No black box warning on record for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

As of the latest FDA labeling reviewed, Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate (EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Lactic Acidosis/Severe Hepatomegaly with Steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. ( 5.2 ) New Onset or Worsening Renal Impairment: Can include acute renal failure and Fanconi syndrome. Avoid administering efavirenz, lamivudine and tenofovir disoproxil fumarate tabl

No black box warning on record for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Lactic Acidosis/Severe Hepatomegaly with Steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity. ( 5.2 ) New Onset or Worsening Renal Impairment: Can include acute renal failure and Fanconi syndrome. Avoid administering efavirenz, lamivudine and tenofovir disoproxil fumarate tabl

Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Black Box Warning

No black box warning on record for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Other warnings & precautions

Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Black Box Warning

No black box warning on record for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate

Other warnings & precautions